Would you proceed to anthracycline based neoadjuvant regimen for locally advanced triple negative breast cancer without clinical response to neoadjuvant paclitaxel or proceed to surgery?

While a lack of response to paclitaxel (don't you now wish that you had added carboplatin?) is concerning and could indicate that the patient has a type of TNBC that responds poorly to chemotherapy, such as AR+, the patient may respond to a different chemo regimen and thus you should proceed to trea...

Couldn’t agree more with the previous messages. For a drug-resistant TNBC in the neoadjuvant setting, we would continue neoadjuvant therapy unless there is a clear progression of the disease in the breast/nodes or development of metastasis. However, based on the current data, those with low pCR (bas...